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Introduction: Adeno-associated virus (AAV)-based gene therapy for haemophilia
presents a challenge to the existing structure of haemophilia centres and requires a
rethink of current collaboration and information exchange with the aim of ensuring a
system that is fit-for-purpose for advanced therapies to maximise benefits and min-
imise risks. In Europe, a certification process based on the number of patients and
facilities is offered to the haemophilia centres by European Haemophilia Network
(EUHANET).
Aim and methods: This joint European Association for Haemophilia and Allied Disor-
ders (EAHAD) andEuropeanHaemophilia Consortium (EHC) publication describes cri-
teria for centres participating in gene therapy care that require a reassessment of the
infrastructure of comprehensive care and provides an outlook on how these criteria
can be implemented in the future work of haemophilia centres.
Results: The core definition of a haemophilia treatment centre remains, but additional
roles could be implemented. Amodifiable ‘hub-and-spoke’ model addresses all aspects
associated with gene therapy, including preparation and administration of the gene
therapy product, determination of coagulation and immunological parameters, joint
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score and function, and liver health. Thiswill also include the strategy onhow to follow-
up patients for a long-term safety and efficacy surveillance.
Conclusion:We propose a modifiable, networked ‘hub and spoke’ model with a long
termsafety andefficacy surveillance system. This approachwill be progressively devel-
opedwith the goal ofmaking haemophilia centres better qualified to deliver gene ther-
apy and to make gene therapy accessible to all persons with haemophilia, irrespective
of their country or centre of origin.
KEYWORDS
gene therapy, haemophilia care, haemophilia treatment, treatment centres
1 INTRODUCTION
The treatment of haemophilia and adherence to prophylactic ther-
apy has been significantly improved by the introduction of long-
acting factor concentrates and non-factor therapy based on innovative
technologies.1 Additionally, haemophilia care, including the availabil-
ity of factor concentrates and medical expertise, patient information
and organisation have made considerable progress in recent decades.
According to the third edition of theWorld Federation of Haemophilia
(WFH) guideline, regular prophylaxis should start at a young age
until an alternative long-term therapy such as gene therapy becomes
available.2 In line with these improvements, prophylaxis is now recom-
mended for all patients, aiming for trough levels of at least 3–5%when
using extended half-life Factor VIII (FVIII) and IX (FIX) concentrates.1
The complex treatment of haemophilia has been managed by spe-
cialised, interdisciplinary European Haemophilia Comprehensive Care
Centres (EHCCC’s) and European Haemophilia Treatment Centres
(EHTC’s) that offer a wide range of clinical and laboratory services as
well as the supply of factor concentrates for home treatment.3
Haemophilia treatment centres (HTC’s) have been established to
ensure the multidisciplinary care model with access to clinical spe-
cialties, emergency departments and appropriate laboratory facilities.
Diagnostic and treatment tools were optimized to prevent bleeding
and treat haemophilia-related comorbidities.
The European Haemophilia Network (EUHANET) project identified
409 haemophilia centres in Europe.4 It established a certification pro-
cess based on the number of patients and facilities offered by the
haemophilia centres. Centres are able to apply to be comprehensive
care centres or haemophilia treatment centres.
The arrival of advanced therapies and particularly gene therapy
requires further thought on appropriate ways to organize European
haemophilia treatment centres. We propose a modifiable, networked
‘hub and spoke’modelwith a long-term safety and efficacy surveillance
system.
2 GENE THERAPY AS A CHALLENGE FOR
HAEMOPHILIA CENTRES
Gene therapy offers the promise for haemophilia patients to receive
a one-time treatment, achieving potentially clinically meaningful fac-
tor levels that could last for years or decades, enabling independence
from frequent and repeated administration of a prophylaxis agent.
Some adeno-associated virus (AAV) vector-mediated gene transfer in
haemophilia A and B are already in phase III trials.5 It is expected that
the first FVIII and FIX gene therapy products will be approved in 2022,
becoming available soon thereafter for patients with haemophilia in
Europe,Middle East and the United States.
Although gene therapy strategies have been in development for
more than 20 years, gene therapy for haemophilia is still a new and
experimental method, with very few patients treated so far. Some
adverse events are known from the studies published so far, remaining
uncertainties and potential unknowns are widely discussed: short-
term or mid-term safety issues include allergic reactions and liver
enzyme elevations, which require prompt management. Patients and
their caregivers have to deal with some uncertainties that are not
encountered from current, conventional prophylaxis treatments.6
The response rate and persistence of expression may vary and, thus
far, cannot be reliably predicted.7For some patients who experience
a loss of factor expression with re-emergent spontaneous bleed-
ing, re-engagement with conventional comprehensive care will be
necessary.8
The level of factor expression is considered the appropriate pri-
mary endpoint in gene therapy studies on haemophilia.9 The labora-
tory equipment of haemophilia centres includes a well-established,
validated set of coagulation factor tests, which are able to quantify
the effect of different treatments, assessing the efficacy and potential
complications (e.g., inhibitors) of a given therapeutic agent. Measure-
ment of factor levels in gene therapy, however, may require specific
factor assay selection on account of there being discrepancy between
the one-stage and chromogenic assay, with the one-stage assay being
1.6 times greater than the chromogenic assay in both HA and HB gene
therapy.10 In addition, regular laboratory values in blood such as blood
count, haemoglobin and clinical chemistry including kidney and liver
markers need to be measured. Liver enzymes are particularly impor-
tant in gene therapy, because liver-specific gene therapies can cause
liver toxicity, and patients need to be evaluated carefully with expert
hepatologists and immunologists.
The approach of gene therapy for haemophilia is to achieve bet-
ter clinical outcomes and a better quality of life than is possible with
currently available haemophilia products. For this, there should be a
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global effort to make this therapy available to interested patients so
that equal access can be guaranteed.6
With the introduction of gene therapy, the requirements for
EHCCC’s and EHTC’s will change, representing a fundamental
paradigm shift in the treatment of haemophilia, with many potential
consequences for haemophilia centres. Among other things, long-term
follow-up in clinical trials and registries is required and a coordinated
approach by all stakeholders is necessary to ensure safe and effective
application, as well as to initiate immediate coordinated action in
case of unexpected safety problems, with the aim of offering every
patient an optimal chance of success and provide better information
for decision-making by both clinician and patient.11,12
An additional new taskwould be to follow andmonitor the selection
criteria for gene therapy in patients. Up to now, a significant number
of patients cannot be treated with gene therapy, as in many cases
exclusion criteria for gene therapy exist, for example, the presence
of pre-existing antibodies against AAV, age younger than 18 years
or comorbidities.5 In clinical trials, gene therapy also requires a non-
routine measurement of cellular and humoral immunity as well as the
determination of the release of vector particles through body fluids
(vector shedding). One of the selection criteria for the majority of
gene therapy platforms is the absence of already existing antibodies
to AAV, which may limit the possibility of liver cell transduction and
consequent factor expression. After successful transduction, a T-cell
dependent response has been described that leads to transaminitis
and liver cell damage.5 None of these tests are standardized or utilise
commonly used reagents, which makes inter- and intra-laboratory
comparison of antibody levels or T-cell titres difficult. However, it is
not clear what tests need to be transposed from the clinical trials into
service delivery and what can be dropped. These criteria may change
over time based on evidence from subsequent studies that include
these patient groups. Further studies are planned in patients with
coagulation factor inhibitors and in children and adolescents.
Very few centres will currently have access to assays for measur-
ing specific B- and T-cell immune responses, and strategies should be
developed for collaboration with experienced laboratories or industry.
In addition to laboratory issues, time, resources and clinical capacity
to deliver gene therapy, expertise to monitor and manage unexpected
adverse events or to determine the dosage or duration of prophylac-
tic and concurrent immune suppressive treatment when necessary to
overcome liver toxicity, is required.13 Protocols on different strategies
for immunosuppression as performed in the different studies should be
provided.
More personalised discussions about patient expectations would
be appropriate, anticipating the likely changes in the circumstances
affecting patients’ lifestyle after discontinuing regular prophylactic
treatment. Psychological support needs to be provided in a robust and
consistent manner, as early as the decision-making stage on whether
or not to choose gene therapy, considering its possible short and long-
term safety problems or other unknown factors, for example, the dura-
bility of gene expression.9
Lack of knowledge and familiarity with gene therapy has also been
expressed by European pharmacists, including concerns about phar-
TABLE 1 Challenges of gene therapy for haemophilia centres
∙ Patient informed consent and eligibility tests
∙ Administration of a gene therapy construct andmanaging
infusion related reactions
∙ Monitoring variability of factor expression and deciding when to
stop prophylactic treatment
∙ Close cooperationwith hepatologists and immunologists
∙ Monitoring of short-, medium- and long-term adverse events
∙ Retaining patient engagement for follow up
∙ Long-term follow-up by an accurate surveillance system
∙ Direct and indirect costs reimbursement for administration of
gene therapy and follow-ups
macokinetic and pharmacodynamic interactions.14 In addition, condi-
tions for appropriate equipment may be lacking and must be prepared
accordingly, such as facilities for storage, handling and reconstitution
of gene therapies.15 In some countries not only healthcare legislation
applies but also environmental legislation. This is, for example, the case
in Holland where one needs an environmental permit and all academic
hospitals need to have a biosafety officerwhen dealingwith genetically
modified organisms.
The knowledge gap in gene therapy has led to the development
and implementation of training programmes such as ‘Gene therapy for
haemophilia: An ISTH training initiative’ that will be able to guide insti-
tutional preparation when approved gene therapy products become
available. Additional efforts in post-marketing surveillance, patient
registration and data collection have been initiated byWFH in collabo-
ration with the International Society on Thrombosis and Haemostasis
(ISTH), the EuropeanAssociation forHaemophilia andAlliedDisorders
(EAHAD), the European Haemophilia Consortium (EHC), the National
Haemophilia Foundation (NHF) and other organizations.16,17
Gene therapy for haemophilia presents a challenge to the existing
structure of haemophilia centres and requires an enhanced modality
of collaboration and information sharing with the aim of maximising
benefits and minimising risks. Table 1 describes the challenges of gene
therapy for haemophilia that can only be addressed through a collab-
orative effort among haemophilia centres and requires a re-evaluation
of infrastructure and comprehensive care.
3 THE HUB AND SPOKE MODEL
OF DELIVERING GENE THERAPY
IN HAEMOPHILIA CENTRES
The proposed ‘hub and spoke’ model aims to coordinate a com-
plete package of care of gene therapy delivery, ensuring suffi-
cient time and expertise for patient counselling and informed con-
sent, with clear demarcation of responsibility for subsequent dosing,
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micromanagement (close surveillance) of the immediate post infusion
time period and then offering patient centric long term follow-up and
surveillance. We recognise that this model will need to be modifiable
for different countries and even between regions of the same country.
There are broadly 2 scenarios:
1- The ‘Hub’ is a HTC experienced in both comprehensive care and
gene therapy (GT) and the ‘Spoke’ is another HTCwith no or mini-
mal GT experience, which will be the home centre for the patient.
The Hub in this scenario will take the lead in all aspects of GT
delivery pre infusion and post infusion. Although the patient may
be managed locally (visits, routine bloods, MDT review), decisions
relating to GT will remain a collaborative discussion between the
Hub and Spoke staff to ensure optimum patient outcomes.
2- In this scenario the ‘hub’ is a dosing centre (GT delivery experi-
enced) and the ‘Spoke’ is a management centre (also GT experi-
enced). To offer a full range of gene therapy platforms, patientsmay
need to go to other sites for infusion, as it is possible that not all
centres will have all platforms open, but return to their ‘home’ cen-
tre for subsequent management.
In either scenarios, it is important to guarantee that hub and spoke
centres follow all patients regularly, particularly in the first year with
well-defined and structured protocols.
Clinical gene therapy studies have been conducted in specialized
HTC’s, with HTC’s often benefiting from their research pharmacies,
clinical research centres, dedicated research nurses and coordinators.
In the recently published joint statement of EAHAD and EHC, a gene
therapy hub and spoke model was proposed to ensure safe intro-
duction, use, monitoring and optimal learning capacity for all eligible
patients.18
The core, traditional definition of an HTCmay remain, but it may be
useful to add additional tasks to be implemented before and/or after
the administration of gene therapy. A hub and spoke model would deal
with all aspects inherent to gene therapy, including informed consent,
preparation and administration of the gene therapy product, determi-
nation of coagulation and immunological parameters, joint score and
joint function, surgery and liver health, among others. In light of expe-
rience with gene therapy studies, several criteria have emerged that a
gene therapy treatment centre should fulfil. These criteria could only
bemet by a small number of HTCs, which could serve as dosing centres
(hubs) for patients from other HTCs (spokes) with whom close cooper-
ation could be established (Table 2).
In this proposed model, the tasks would be divided according to the
experience and equipment of the partner centres (Table 3). Gene ther-
apy is exclusively prescribed and administered by expert haemophilia
comprehensive care centres (as the hubs) and longitudinallymonitored
by haemophilia treatment centres in close communicationwith the pri-
mary expert hub (as spokes linking into that hub) depending on pre-
existing expertise in each centre (see above scenarios 1 and 2).
In case that the patient was referred for dosing by another HTC,
tests for the gene therapy programandexisting antibodies againstAAV
need to be planned. Confirmation of informed consent should be car-
TABLE 2 Criteria for definition of gene therapy delivering centre
(hub centre)
∙ Experience obtained in previous gene therapy trials (or
specialists who can provide timely expertise in gene therapy) or
available mentorship program
∙ Ability to order, store, prepare and administrate the gene
therapy product
∙ Provision of informed consent
∙ Ability to performdiagnostic tests for the gene therapy program
and follow-up of patients (e.g., modified chromogenic test)
∙ Close cooperationwith other HTC’s (interaction betweenHUB
and SPOKE)
∙ Knowledge in timely diagnosis andmanagement of adverse
events in gene therapy
∙ Close cooperationwith hepatologists and immunologists
∙ Protocols on different strategies for immunosuppression as
performed in the different studies
∙ Longitudinal data collection and evaluation in gene therapy; for
example, national and/or international registries
ried out to ensure all patients knowledge is up to date and reduce the
risk of ‘buyer’s remorse’ (regretting the decision to proceed with an
irreversible process).
After the referredpatienthasbeendosed, the ‘home’HTCandspoke
centrewould remain responsible for patient follow-up,which shouldbe
done in close cooperation with the dosing centre, for example, in case
of adverse events and the need for immunosuppressive treatment and
any eventual need for inpatient care.
Particularly in the early post-dosing period, further regular follow-
up by the hub centre can be performed,which in the long-termcould be
expanded to occasional reviews to detect unexpected long-term safety
issues.
Management of bleeding events would remain the responsibility
of the spoke centre. While the regular follow-ups are more intense
in the first year, long-term follow-up, reporting and monitoring of
adverse events and inclusion in a gene therapy databasewill need to be
determinedwithin that specific network of centres delivering the GT.
4 EDUCATION OF THE MULTIDISCIPLINARY
TEAM
In general, not only general tasks forHTCs change, but also the respon-
sibilities of their multidisciplinary teams. The haemophilia nurse of the
involved centres is likely to remain the patient’s primary contact per-
son to ensure coordination between the various centres, specialties
and laboratories. Psychological support is likely to be required for sev-
eral years after gene therapy and could become even more important
as patients might experience chronic, or acute uncertainties and fears
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Renew this discussion before dosing 2–3 times during the pre-dosing process
Patient selection Review of the eligibility criteria Patient recruitment or retention
∙ Monitoring the eligibility criteria
∙ Identifying possible candidates
Laboratorymonitoring and
performance of diagnostic tests
for the gene therapy program
Required test before treatment:
-existing AAV-antibodies
Required test before treatment:Pre-existing
AAV-antibodiesRequired after treatment:
∙ Determination of possible immunological
markers
∙ Coagulation factor levels
Education and training Training of health professionals from other
HTCs andmanagement advice (e.g.,
corticosteroid treatment)
Multidisciplinary team to be trained
Informed Consent Review before dosing Education and regularly follow-up of
patients and physicians
Preparation of the gene therapy
product, dosing
Storage of materials for preparation and
administration
Follow-up
Short-term ∙ Counselling and collaboration
∙ Further regular follow-up can be
performed
∙ Protocols on different strategies for
immunosuppression as performed in the
different studies
∙ Regular follow-up (weekly tomonthly) at
least in year 1),
∙ Initiation of immunosuppressive
treatment
Long-Term (from year 2) ∙ Counselling about long-term risks
∙ Follow-up can expand to occasional
reviews
∙ Regular follow-up (every 3 until 6
months)
∙ Liver health review
Data collection National and international data collection17 National and international data collection17
MDTTeam ∙ Counselling and collaboration ∙ Ongoing support of bleeding episodes or
management of any side effect
∙ Ensure information sharing with Hub
∙ If possible:
Abbreviations: HTC, haemophilia treatment centre; AAV, adeno associated virus; MDT, multidisciplinary team.
after gene therapy, either platform specific ormore generic, depending
on future events in longer term follow up of the global cohorts of gene
therapy recipients.6
The members of the HTC multidisciplinary team should be trained
and provided with up-to-date information on all relevant aspects of
gene therapy with the aim that each member of the HTC is informed
about gene therapy, and patients receive consistent information. Gene
therapy training should alsobe included in theundergraduate andpost-
graduate curricula.
Within the HTC multidisciplinary team, the role of the hepatologist
needs to be defined in terms of their importance and clinical contri-
bution in the recognition and management of short-term and possible
long-term adverse events of gene therapy. It may be prudent to involve
a hepatology specialist in the pre-dosing period to discuss personalised
liver health and potential risks with a gene therapy candidate.
The issue of reimbursement for gene therapy refers to the overall
funding for centres providing gene therapy, and goes beyond the costs
of gene therapy itself. Sustainable funding solutions should be devel-
oped on a national basis including the costs for the hub and spoke cen-
tres’ infrastructure and staff costs.
A close collaboration with pharmaceutical/life science industry
partners is required, taking into account both their past experience and
current gene therapy activity, as well as with scientific organisations,
patient organisations, payers/commissioners and regulatory authori-
ties on how to ensure long term observation and evaluation of gene
therapy recipients.
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5 CONCLUSION
Gene therapy offers the possibility to transform patients’ lives by
enabling a long-lasting periodof high levels for factor expression, possi-
bly into the normal range, after a single therapeutic infusion. Although
many early recipients may have legacy haemophilic arthropathic
changes persisting post GT, such sustained levels of factor expression
is likely to provide sustained freedom from spontaneous bleeds and
normalise risk of traumatic bleeds to that of non-haemophilic peers.
Uncoupling the individual GT recipient from the requirement for reg-
ular administration of a haemostatic therapy to maintain their protec-
tion is likely, in time, to harness a much broader personal ‘freedom’ to
pursue activities and opportunities, both recreational or occupational,
whether close to homeormuch further a field, possibly to parts of their
country (or the globe) that they would have never previously consid-
ered travelling to through necessity of risk assessment for acute care.
Given the complexity and potential complications of gene therapy
administration, it is the responsibility of health professionals to ensure
the prescription, administration andmonitoring of gene therapies. This
proposed ‘hub and spoke’ model according to the joint statement of
the EAHAD and the EHC offers patients the opportunity to receive
gene therapy independent of their location or state of knowledge or
experience of their local haemophilia centres and obtain the best out-
come available in the short and longer term. However, raising aware-
ness and education for both patients and health care personnel (physi-
cians, nurses, physiotherapists, psychologists, lab team) in the wider
network of HTCs is crucial as most follow-up will be done through the
local centres.
Currently, aminority of patients will be eligible for gene therapy but
with time, inclusion criteria will change and more gene therapy prod-
ucts will become available. With more experience it is likely that the
knowledge and also the outlined responsibilities may change, and the
criteria for a hub and a spokemodel could be adjusted accordingly.
The strength of a hub and spoke model for managing gene ther-
apy is to enable standardised gene therapy treatment of haemophilia
patients, regardless of the centre or even country inwhich the patients
are located. In addition, quality criteria could be established and
approved toensure a robust informeddecision,with themaximumben-
efit of gene therapy and the least possible side effects, as well as a
strong working team comprised of pharmacists, nurses, hepatologists,
psychologists, physiotherapists, biomedical scientists and haematolo-
gists.
Thismodel is expected to be dynamic andwould be adaptable based
on gene therapy efficacy and safety data to be better prepare for the
challenges of delivering this therapy type once they are approved.
Although this manuscript only addresses the challenges of AAV-
based gene therapy, it may pave the way for some more specific
future requirements for non-AAV-based approaches and ex vivo gene
therapies.
In summary, gene therapy is becoming an increasingly important
therapeutic option for patients with haemophilia. This therapeu-
tic modality requires additional interaction with other specialties
including hepatologists, and in addition it is important that clinical
experience about nuances of gene therapy is gained and shared.
Further, long-term surveillance is absolutely critical for demonstrating
the long-term safety not just for GT recipients with haemophilia but
also cross referencing with experience and outcomes for patients with
other monogenic disorders undergoing gene therapy.
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